Atomo Diagnostics Limited (ASX:AT1)

Market Cap	16.20M
Revenue (ttm)	3.79M
Net Income (ttm)	-4.97M
Shares Out	810.18M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	824,395
Average Volume	1,855,799
Open	0.0200
Previous Close	0.0200
Day's Range	0.0190 - 0.0210
52-Week Range	0.0140 - 0.0250
Beta	0.85
RSI	54.23
Earnings Date	Oct 26, 2025

About Atomo Diagnostics

Atomo Diagnostics Limited engages in the development and sale of medical devices worldwide. The company offers RDT platforms, including AtomoRapid Pascal, Curie, Galileo, and Elion for blood tests. It also offers Atomo application, a custom mobile application for self-test users, as well as provides digital health solutions. In addition, it provides HIV Rapid self-Tests. Atomo Diagnostics Limited was incorporated in 2010 and is headquartered in Leichhardt, Australia.

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2010
• Employees: 85
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: AT1

Financial Performance

In 2025, Atomo Diagnostics's revenue was 3.79 million, a decrease of -7.20% compared to the previous year's 4.09 million. Losses were -4.97 million, -27.41% less than in 2024.